Patents by Inventor Carla F. Kim

Carla F. Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
    Patent number: 11624093
    Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: April 11, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Kwok-Kin Wong, Chunxiao Xu, Christine F. Brainson, Carla F. Kim, Glenn Dranoff, Peter Hammerman
  • USE OF ALVEOLAR OR AIRWAY ORGANOIDS FOR THE TREATMENT OF LUNG DISEASES AND DISORDERS
    Publication number: 20210030811
    Abstract: Various aspects described herein provide methods of generating alveolar or alveolar/airway organoids from a population of lung cells to differentiate into alveolar or alveolar/airway organoids. Also provided herein are methods and compositions for treating lung disease comprising transplantation of the alveolar or alveolar/airway organoids, or a cell isolated therefrom to a subject.
    Type: Application
    Filed: October 19, 2020
    Publication date: February 4, 2021
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Carla F. KIM, Sharon M. LOUIE, Erhan ARARAT, David RAISER
  • METHODS AND COMPOSITIONS RELATING TO LUNG CELL DIFFERENTIATION
    Publication number: 20190136199
    Abstract: Described herein are methods and compositions relating to the provision and/or differentiation of certain fully differentiated lung cell types, including surfactant producing cells (e.g. club secretory cells), mucus producing (Goblet) cells, mucus-producing goblet like cells, and beating ciliated cells. In some embodiments, one or more of the differentiated lung cell types is present in an organoid. Differentiation of these lung cell types can be induced by contacting lung stem and/or progenitor cells with one or more inhibitors of H3K9me1/2 methyltransferase, e.g., an inhibitor of G9a and/or Glp (EMHT2 and/or EHMT1).
    Type: Application
    Filed: June 8, 2017
    Publication date: May 9, 2019
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Carla F. KIM, Samuel P. ROWBOTHAM, Joo-Hyeon LEE
  • METHODS AND ASSAYS FOR COMBINATION TREATMENT OF CANCER
    Publication number: 20180147226
    Abstract: The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 31, 2018
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Christine M. FILLMORE, Carla F. KIM
  • Methods and assays for combination treatment of cancer
    Patent number: 9895390
    Abstract: The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 20, 2018
    Assignee: Children's Medical Center Corporation
    Inventors: Christine M. Fillmore, Carla F. Kim
  • METHODS AND ASSAYS FOR COMBINATION TREATMENT OF CANCER
    Publication number: 20150320779
    Abstract: The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor.
    Type: Application
    Filed: November 12, 2013
    Publication date: November 12, 2015
    Inventors: Christine M. Fillmore, Carla F. Kim